JP2005508169A - ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物 - Google Patents

２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物 Download PDF

Info

Publication number
JP2005508169A
JP2005508169A JP2003539603A JP2003539603A JP2005508169A JP 2005508169 A JP2005508169 A JP 2005508169A JP 2003539603 A JP2003539603 A JP 2003539603A JP 2003539603 A JP2003539603 A JP 2003539603A JP 2005508169 A JP2005508169 A JP 2005508169A
Authority
JP
Japan
Prior art keywords
cell
protein
expression
nucleic acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003539603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508169A5 (enExample
Inventor
マーク ウィリアムソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2005508169A publication Critical patent/JP2005508169A/ja
Publication of JP2005508169A5 publication Critical patent/JP2005508169A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G01N33/57515—
    • G01N33/5752—
    • G01N33/57535—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003539603A 2001-10-31 2002-10-29 ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物 Pending JP2005508169A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33500601P 2001-10-31 2001-10-31
PCT/US2002/034574 WO2003037257A2 (en) 2001-10-31 2002-10-29 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Publications (2)

Publication Number Publication Date
JP2005508169A true JP2005508169A (ja) 2005-03-31
JP2005508169A5 JP2005508169A5 (enExample) 2006-01-05

Family

ID=23309830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003539603A Pending JP2005508169A (ja) 2001-10-31 2002-10-29 ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物

Country Status (5)

Country Link
US (1) US20030108937A1 (enExample)
EP (1) EP1440080A4 (enExample)
JP (1) JP2005508169A (enExample)
AU (1) AU2002363228A1 (enExample)
WO (1) WO2003037257A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363228A1 (en) * 2001-10-31 2003-05-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
JP2005512529A (ja) * 2001-12-13 2005-05-12 エクセリクシス・インコーポレイテッド βカテニン経路のモディファイヤーとしてのＴＡＯＪＩＫｓおよび使用方法
WO2003074725A2 (en) * 2002-03-01 2003-09-12 Exelixis, Inc. MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
US20070128666A1 (en) * 2003-11-24 2007-06-07 Helen Francis-Lang Ttbks as modifiers of the beta catenin pathway and methods of use
CA2546747A1 (en) * 2003-11-24 2005-06-09 Exelixis, Inc. Ttbks as modifiers of the beta catenin pathway and methods of use
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501038A (ja) * 1999-05-28 2003-01-14 スージェン・インコーポレーテッド 蛋白質キナーゼ
US20020151020A1 (en) * 2001-04-16 2002-10-17 Xianghe Yan Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002363228A1 (en) * 2001-10-31 2003-05-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Also Published As

Publication number Publication date
WO2003037257A3 (en) 2004-01-22
WO2003037257A2 (en) 2003-05-08
US20030108937A1 (en) 2003-06-12
AU2002363228A1 (en) 2003-05-12
EP1440080A4 (en) 2007-12-12
EP1440080A2 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
JP5931336B2 (ja) がんを処置および診断するための組成物および方法
JP2005522999A (ja) 癌を処置するための方法および組成物
JP2010246558A (ja) 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
WO2005000088A2 (en) Expression profile of pancreatic cancer
EP1280937A2 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
JP4538316B2 (ja) 抗オキサリプラチン耐性剤
JP2005508169A (ja) ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物
US7037668B2 (en) Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
HUP0303905A2 (hu) KIAA-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
US20060088881A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
US20030114408A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604
US20030124593A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
US20030113777A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
US20030113776A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394
US20030104455A1 (en) Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
JP2005513422A (ja) 癌を処置するための方法および組成物
US20030087245A1 (en) Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
JP2004535788A (ja) １０２１８を用いる循環器疾患を治療する方法および組成物
HK1206256B (zh) 抗cxcr1组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090512